Immune Checkpoint Inhibitor Outcomes in NSCLC Across Populations and Practice Settings
{{output}}
Introduction: Immune checkpoint inhibitor (ICI) clinical trials generally enroll non-Hispanic White patients at academic or private practice settings. ICI outcomes at safety-net settings and across diverse populations remain limi... ...
